PriceTargets.com logo

CTI BioPharma - CTIC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.09 As of 06/26/2023 01:00 AM ET
+0 (0.00%)
Get New CTI BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTIC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for CTI BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.09.

This chart shows the closing price for CTIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in CTI BioPharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
5/15/2023Stifel NicolausDowngradeBuy ➝ HoldLow
5/11/2023JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
5/10/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
5/10/2023Lake Street CapitalDowngradeBuy ➝ HoldN/A
4/19/2023Needham & Company LLCReiterated RatingBuy$9.00Low
4/17/2023TD CowenLower TargetOutperform$10.00 ➝ $8.00N/A
3/7/2023JMP SecuritiesReiterated RatingMarket Outperform$9.00Low
3/6/2023Needham & Company LLCReiterated RatingBuy$9.00Low
10/17/2022SVB LeerinkInitiated CoverageOutperform$13.00Low
9/1/2022Jefferies Financial GroupInitiated CoverageBuy$13.00Low
8/9/2022Needham & Company LLCBoost TargetBuy$8.00 ➝ $9.00Low
8/9/2022JMP SecuritiesBoost TargetMarket Outperform$6.00 ➝ $9.00Low
7/7/2022CowenInitiated CoverageOutperform$10.00N/A
7/7/2022CowenInitiated CoverageOutperform$10.00N/A
6/6/2022Needham & Company LLCReiterated RatingBuy$8.00High
6/6/2022JMP SecuritiesReiterated RatingBuy$6.00High
3/2/2022Needham & Company LLCBoost TargetBuy$5.00 ➝ $8.00High
3/2/2022JMP SecuritiesBoost TargetMarket Outperform$4.00 ➝ $5.00High
3/1/2022Brookline Capital AcquisitionBoost TargetBuy ➝ Buy$7.20 ➝ $12.00High
3/1/2022Brookline Capital ManagementBoost TargetBuy ➝ Buy$7.20 ➝ $12.00High
12/15/2021JMP SecuritiesReiterated RatingBuy$4.00High
12/1/2021Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00High
12/1/2021JMP SecuritiesReiterated RatingBuy$4.00High
11/17/2021JMP SecuritiesReiterated RatingBuy$4.00High
11/15/2021Brookline Capital ManagementReiterated RatingBuyHigh
10/4/2021Needham & Company LLCReiterated RatingBuy$6.00Medium
8/31/2021JMP SecuritiesReiterated RatingBuy$4.00Low
8/9/2021BTIG ResearchInitiated CoverageBuy$7.00High
7/30/2021JMP SecuritiesReiterated RatingBuy$4.00Low
6/1/2021Lake Street CapitalBoost TargetBuy$13.00 ➝ $15.00High
5/6/2021Stifel NicolausInitiated CoverageBuy$5.50High
1/4/2021Lake Street CapitalBoost TargetBuy$8.00 ➝ $13.00N/A
10/23/2020Brookline Capital ManagementInitiated CoverageBuy$7.00Medium
9/30/2020Needham & Company LLCBoost TargetBuy$3.50 ➝ $6.00Low
7/5/2020Lake Street CapitalReiterated RatingBuy ➝ Market Perform$4.00Medium
6/24/2020JMP SecuritiesInitiated CoverageOutperform$3.00Low
4/27/2020Needham & Company LLCInitiated CoverageBuy$3.50High
2/3/2020Needham & Company LLCReiterated RatingBuy$3.50High
12/10/2019Needham & Company LLCReiterated RatingBuy$4.00High
11/5/2019Needham & Company LLCReiterated RatingBuy$4.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
CTI BioPharma logo
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $9.09
Low: $9.09
High: $9.09

50 Day Range

MA: $9.06
Low: $8.91
High: $9.10

52 Week Range

Now: $9.09
Low: $4.01
High: $9.10

Volume

N/A

Average Volume

4,496,004 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of CTI BioPharma?

The following Wall Street analysts have issued research reports on CTI BioPharma in the last twelve months: JMP Securities, Lake Street Capital, Needham & Company LLC, Stifel Nicolaus, StockNews.com, and SVB Securities.
View the latest analyst ratings for CTIC.

What is the current price target for CTI BioPharma?

0 Wall Street analysts have set twelve-month price targets for CTI BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CTI BioPharma in the next year.
View the latest price targets for CTIC.

What is the current consensus analyst rating for CTI BioPharma?

CTI BioPharma currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CTIC, but not buy more shares or sell existing shares.
View the latest ratings for CTIC.

What other companies compete with CTI BioPharma?

Other companies that are similar to CTI BioPharma include Pieris Pharmaceuticals, Deciphera Pharmaceuticals, Collegium Pharmaceutical, Gemini Therapeutics and AbCellera Biologics. Learn More about companies similar to CTI BioPharma.

How do I contact CTI BioPharma's investor relations team?

CTI BioPharma's physical mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company's listed phone number is (206) 282-7100 and its investor relations email address is [email protected]. The official website for CTI BioPharma is www.ctibiopharma.com. Learn More about contacing CTI BioPharma investor relations.